News | Radiation Therapy | January 29, 2016

Position created to increase research participation and collaboration in the field of radiation oncology

January 29, 2016 — The American Society for Radiation Oncology (ASTRO) recently welcomed Judy Keen, Ph.D., as its director of scientific affairs, a position created to grow research participation and collaboration in the field of radiation oncology.

As the ASTRO lead on scientific affairs, Keen will develop and implement initiatives that promote clinical, translational and basic radiation research, with the ultimate goal of advancing both science and evidence-based patient care throughout the radiation oncology community. Efforts involved in this push to grow research participation among radiation oncologists include managing the various funding mechanisms offered by ASTRO — such as its junior faculty awards and seed grants — as well as finding and promoting opportunities from external funding agencies to share with ASTRO members, which include nearly all practicing radiation oncologists in the United States.

Keen also will spearhead efforts to develop broader collaborations within the cancer research community, thereby responding to the growing need to eradicate the silos that can impede scientific progress. Among other roles, Keen will serve as ASTRO’s primary scientific liaison to internal and external partners involved in performing and promoting biomedical research, including the ASTRO Science Council, federal agencies, other medical societies, coalitions, the biopharmaceutical industry and policymakers.

Keen brings a wealth of diverse experience conducting and managing research projects to her new position. Prior to joining ASTRO, Keen was director of research collaborations for the National Breast Cancer Coalition (NBCC), where she led scientific oversight for multiple programs.

Before NBCC, she worked at the National Cancer Institute within the National Institutes of Health (NIH), first as a health science analyst in the Office of Science Planning and Assessment, then as program director for the NIH Genotype Tissue Expression (GTEx) project within the Biorepository and Biospecimen Research Branch. The GTEx effort included curating a collection of genomic and clinical data from more than 900 donors that was designed to explore genetic variability in humans and the changes that lead to disease.

Keen also spent several years as an assistant professor in the department of medicine at the Robert Wood Johnson Medical School at the University of Medicine and Dentistry of New Jersey, where she focused on ways to improve responses to chemotherapy in breast cancer.

Keen earned her doctorate in physiology and completed her postdoctoral training in breast cancer research at Johns Hopkins University in its Schools of Public Health and Medicine, respectively. She also earned a master of science degree in biotechnology from Hopkins and a bachelor of science degree in biology from Gettysburg College in Pennsylvania.

“Judy understands the fundamental role of research and science in helping radiation oncology teams provide the best possible care to their patients, which we can see from her extensive background both conducting research and promoting scientific activities,” said Laura Thevenot, chief executive officer of ASTRO. “I welcome her expertise and look forward to leveraging ASTRO’s position as the world’s premier radiation oncology society to further advance scientific knowledge within radiation biology and oncology.”

For more information: www.astro.org


Related Content

News | Radiation Dose Management

April 25, 2024 — BIOTRONIK, a leading global medical technology company specializing in innovative cardiovascular and ...

Time April 25, 2024
arrow
News | Artificial Intelligence

March 28, 2024 — As artificial intelligence (AI) makes its way into cancer care – and into discussions between ...

Time March 28, 2024
arrow
News | Prostate Cancer

March 27, 2024 — A minimally invasive treatment using MRI and transurethral ultrasound instead of surgery or radiation ...

Time March 27, 2024
arrow
Videos | Radiation Oncology

In the conclusion of this 3-part video series on recent advancements in diagnostic radiology, current editorial advisory ...

Time March 19, 2024
arrow
News | Breast Imaging

March 18, 2024 — QT Imaging Holdings, Inc., a medical device company engaged in research, development, and ...

Time March 18, 2024
arrow
Feature | Radiation Oncology | By Christine Book

Appreciating the considerable advances in the clinical application of artificial intelligence (AI) within healthcare ...

Time March 06, 2024
arrow
News | FDA

March 1, 2024 — Varian, a Siemens Healthineers company, announced that it has received 510(k) clearance from the U.S ...

Time March 01, 2024
arrow
News | Breast Imaging

February 22, 2024 — The FAST-Forward randomized trial from the UK found that ultrahypofractionated whole breast ...

Time February 22, 2024
arrow
News | Radiation Oncology

February 22, 2024 — The National Institutes of Health has launched a clinical trials network to evaluate emerging ...

Time February 22, 2024
arrow
News | Radiation Oncology

February 14, 2024 — Accuray Incorporated announced that the team at Quebec’s Montérégie Integrated Cancer Center, part ...

Time February 14, 2024
arrow
Subscribe Now